Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus

AIM. To evaluate the effect of sitagliptin in combination with metformin on glucose toxicity and lipotoxicity in patients with type 2 diabetes mellitus. MATERIALS AND METHODS. Eighty-two overweight and dyslipidemic patients (mean age 55.3±9.1 years) who had not achieved the goal levels of glycated h...

Full description

Bibliographic Details
Main Authors:	A S Ametov, D G Gusenbekova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2014-08-01
Series:	Терапевтический архив
Subjects:	type 2 diabetes mellitus dipeptidyl peptidase-4 inhibitors sitagliptin metformin fat metabolism
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/31576

Similar Items

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
by: Aleksander Sergeevich Ametov, et al.
Published: (2015-07-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
by: Yuya Tsurutani, MD, PhD, et al.
Published: (2017-01-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

The renoprotective effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on adenine-induced kidney disease in rats
by: Aly M. Abdelrahman, et al.
Published: (2019-02-01)

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
by: Tzu-Lin Yang, et al.
Published: (2016-04-01)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
by: Olesya M. Taylor, PharmD, BCPS, et al.
Published: (2020-01-01)

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
by: Eugene Yu-Chuan Kang, et al.
Published: (2021-06-01)

Time to exacerbation of heart failure is longer in Malaysian population on dipeptidyl peptidase-4 inhibitor
by: J Hasan, et al.
Published: (2017-01-01)

Comparing the Effect of Dipeptidyl-Peptidase 4 Inhibitors and Sulfonylureas on Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Prospective Open-Label Study
by: Po-Chung Cheng, et al.
Published: (2019-10-01)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021-04-01)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Shusuke Yagi, et al.
Published: (2015-08-01)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
by: Xin Wei, et al.
Published: (2021-08-01)

Dipeptidyl peptidase-4 inhibitors use in clinical practice
by: Tatiana B. Morgunova, et al.
Published: (2019-04-01)

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-10-01)

Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
by: E V Oskola, et al.
Published: (2013-09-01)

Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
by: Wang N, et al.
Published: (2019-08-01)

A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors
by: Kentaro Izumi, et al.
Published: (2019-06-01)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
by: Dimitrios Patoulias, et al.
Published: (2021-08-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
by: Masato Furuhashi, et al.
Published: (2020-06-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
by: Chia-Yu Chang, et al.
Published: (2017-12-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Elisabetta Bigagli, et al.
Published: (2020-03-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
by: Yuriko Nakaoku, et al.
Published: (2019-05-01)

Dipeptidyl peptidase 4 inhibitors in modern domestic practice
by: A. S. Ametov, et al.
Published: (2020-05-01)

The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
by: Shin S, et al.
Published: (2016-03-01)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019-12-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
by: Yohei Kawaguchi, et al.
Published: (2019-03-01)

A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
by: Maneesha Khalse, et al.
Published: (2018-01-01)

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study
by: Linong Ji, et al.
Published: (2021-04-01)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019-03-01)

Cannot write session to /tmp/vufind_sessions/sess_4uiijvp3frv2dr9if8jeitete1